Headway vs Alma vs Grow Therapy: Which Should You Join?

Choosing between Headway, Alma, and Grow Therapy comes down to a process rather than a winner: get the code-level rate sheet for your top CPT codes from each platform that carries the dominant payer in your state, compare the math, and treat whichever one you pick as scaffolding you will take down later. Among prescribers we have watched make this choice, the pattern is consistent. Headway is free to join and takes a slice of each reimbursement. Alma charges a membership fee, currently $1,140 per year on Alma's own pricing page as of July 5, 2026, and passes reimbursements through. Grow Therapy sends patients fastest and pays the least. Which one wins depends almost entirely on your state and your payer mix, and the numbers below show swings large enough to reverse the ranking between two states.

One timing note before the comparison: on July 15, 2026, Aetna cuts rates for clinicians billing through Alma, including paying 99215 at the 99214 rate. If Aetna is your target payer, read what the Aetna rate cut means for prescribers alongside this comparison, because it changes Alma's math specifically.

How do the three platforms charge you?

The business models differ more than the marketing suggests, and the difference compounds with volume.

The flat-fee versus percentage question turns on volume. At $1,140 per year, Alma costs you the equivalent of about five to eight visits annually. A 20 percent cut on a full day per week of insurance work costs far more than that. If you plan one insurance day per week at roughly $170 average reimbursement, a 20 percent cut runs about $1,600 per year per weekly slot filled, so a percentage model overtakes Alma's fee somewhere around the second weekly patient. The catch: this only holds where Alma's underlying rates are comparable, and they are not in every state.

What do the platforms actually pay psychiatric prescribers?

Real reimbursements reported by prescribers between 2024 and early 2026, for the E/M plus psychotherapy add-on combinations cash-pay-curious prescribers actually bill. These are clinician-reported figures rather than published fee schedules; treat them as ranges to verify against your own quotes.

Three patterns matter more than any single cell in that table:

• State reverses the ranking. In Washington, prescribers found Alma's rates meaningfully higher than Headway's for the same insurers. In California, one child psychiatrist found Headway paying roughly double Alma for a 30-minute med management visit. Neither platform is "the higher-paying one" nationally.
• Grow runs low. One prescriber who compared reimbursement for the same patient across platforms found Grow paying roughly a third less than Headway, and left over it. Grow's counterweight is patient volume and multi-state reach, covered below.
• The payer matters more than the platform. In Washington, BCBS plans cover roughly half of insured patients while Aetna covers under 10 percent, and the platforms carry different payers in each state. A great rate on a payer nobody in your area has is worth nothing. Ask which payers dominate your target patients' employers first, then ask which platform carries those payers.

Also ask what you are allowed to decline. Prescribers report you do not have to accept every plan a platform credentials you with. One psychiatrist accepts only the two best-paying plans on her panel and routes everyone else to her cash practice, which is the standard move for anyone using a platform while transitioning toward cash pay.

Which platform actually sends patients?

Referral flow is the strongest argument for Grow and the weakest for Headway. One California PMHNP tracked six referrals from Alma in a single week while Headway sent zero over the same window. Another prescriber went from a handful of cash patients after six months of solo marketing to more than 50 insurance patients in about three months on Grow, at two to three new patients per week. Headway clinicians who want volume typically buy it separately: Zocdoc reportedly runs about $70 per booked lead, or around $2,000 per month for a multi-provider practice that tracked 45 to 50 new evaluations monthly at that spend.

Two caveats. First, referral flow varies by market as much as rates do, so weight local reports over national reputation. Second, more flow is only good if you want it. Advertising insurance acceptance on a directory profile brought one prescriber 10 to 20 inquiries per day, which is unmanageable for a solo practice. Platform referrals fill schedules with general-psychiatry insurance patients, and several clinicians noticed a year later that their practice had drifted away from the niche they set out to build. If the plan is a cash practice, cap the insurance side deliberately: limit the days, limit the plans, and keep marketing the cash side separately.

What goes wrong, and how do you protect yourself?

The expensive failures reported by clinicians are credentialing errors and unreachable support, and one story covers both. A psychiatric NP saw patients for six months believing she was in-network, then learned she had never actually been credentialed with the BCBS plan covering about half her panel. She described the financial hit as nearly practice-ending. A second clinician spent months onboarding, while paying $600 per month for a collaborating physician, before reaching a human who told her the platform did not carry BCBS in her state at all.

The protective habits that follow from those stories:

• Verify credentialing yourself. Call the payer and confirm your effective date before you book the first patient under that plan, because the platform dashboard is a claim, and the payer's answer is the fact.
• Assume support will be forms-only and slow. Clinicians consistently report no phone or email channel at Headway. Read each platform's Better Business Bureau complaint feed before joining; the recurring themes are the real risk list.
• Reread your fee schedule quarterly. One prescriber's rates dropped 10 percent without notice; she contested it, citing the 30-day-notice clause in her contract, and the old rates were restored.
• Budget for the first-payment hold. Payers hold initial payments 30 to 60 days while the billing relationship is established, so expect one to two months of unpaid insurance work at the start.
• Confirm who collects copays. One clinician lost meaningful copay revenue because the platform did not require a card on file from patients. Your own intake policy should require one regardless.

How hard is each platform to exit?

Easier than any alternative, which is the strongest argument for using one at all. Headway, Alma, and Grow bill under their own group NPI and EIN, so your individual NPI and your practice entity never become in-network. You can close to new platform patients with a toggle and resign entirely without your cash practice ever having been entangled. A direct payer contract is the opposite: it can legally obligate you to see any patient with that insurance at contracted rates, and clinicians report exits that drag on with the payer still listing them in-network after termination.

Contract fine print still applies. Alma has stated it does not refund annual memberships canceled mid-term, so time your exit against your renewal date. And mind the July 15 Aetna change: a platform's rates can be repriced by a payer negotiation you were never part of, which is the structural cost of renting someone else's contract.

The exit math is better than most prescribers fear. When patients lost in-network coverage with one psychiatrist, roughly 60 percent stayed and paid cash rather than transfer care. Prescribers planning the move to cash typically assume 30 percent conversion to be safe, then work out how many platform patients they need before flipping. On the operations side the exit is mostly paperwork: download your notes before resigning, and have your own systems ready to generate superbills so patients can claim out-of-network benefits. Practices running on Eureka do this part automatically, since superbill generation is built in, but whatever you use, have it working before the first converted patient asks.

"Platform economics are rental economics: you are renting a payer contract you do not control, and the rent can be repriced at renewal," says David Cohen, CPA, JD, who reviewed this article. "Take the weekly payments while they serve you, but read the termination and notice clauses the day you sign, because the platforms' one genuine structural advantage is that leaving is cheap."

Which should you join? A decision framework

Match the platform to your situation rather than to a ranking:

• You need income fast and volume matters most. Grow Therapy fills schedules fastest in the markets our sources practiced in, at the lowest rates of the three. Reasonable as a short bridge if you set a review date and track the per-visit gap against Headway.
• You want the best rates and can wait for volume. Get code-level quotes from both Headway and Alma for your two or three top CPT combinations in your state. The spread between them routinely exceeds 30 percent, in either direction. Pick on the numbers, and note the Aetna change if Aetna is central to your plan.
• You want one insurance day while building a cash practice. Credential with the one or two best-paying plans only, on whichever platform carries them, and keep every other channel pointed at your cash practice. One major payer is usually enough to fill a day.
• You are deciding whether to take insurance at all. That is the bigger fork, and it comes before this one: the honest comparison of insurance-based versus cash-pay practice and what to charge if you go cash will tell you whether you need a platform in the first place.

Whichever you choose, write down the exit condition on day one: the panel size, the monthly revenue, or the date at which you will reassess. The prescribers who come to regret these platforms skipped that step, and woke up two years later running a practice the platform designed for them.